Mg Sulfate Injection 50% (Magnesium Sulfate Hydrate)

Adult administration

○ Seizures due to hypomagnesemia: Administer 1 to 2 g of magnesium sulfate by intravenous injection (4.05 to 8.1 mmol). ○ Eclamptic seizures: Administer 4 to 5 g of this medication by intravenous injection over 10 minutes (16.2 to 20.25 mmol). ○ Prevention of uterine contractions: Administer 4 g of this medication by intravenous injection initially (16.2 mmol). An additional 1 g may be administered thereafter. ○ Electrolyte supplementation (hypomagnesemia): Administer 1 g of this medication by intramuscular injection every 6 hours for a total of 4 doses; alternatively, 5 g of this medication may be added to 5% dextrose injection or 0.9% saline solution and administered intravenously over 3 hours. Careful monitoring of the patient's renal excretion function is critical when treating deficiency. ○ Children: The safety of this medication has not been tested.

Child administration

The safety of this medication has not been tested.

As this medication is given as an injection, glass fragments may be mixed in when breaking the glass ampoule, so caution is required when using it in children or elderly patients. It should not be administered to patients with poor kidney function, those in a coma, patients with high blood magnesium levels, patients with heart conduction disorders, or patients with myasthenia gravis. It should be used cautiously in children with intestinal parasitic infections or in patients with heart disease. Using this medication may cause gastrointestinal symptoms such as vomiting or dry mouth, and rarely symptoms like heart rhythm disturbances, vasodilation, headaches, or tremors may occur. In case of overdose, magnesium poisoning can occur, leading to hypotension, respiratory distress, and cardiac suppression, requiring immediate treatment. Caution is needed when this medication is used alongside other central nervous system depressants, as the effects may be enhanced, and absorption may be reduced when taken with certain antibiotics or iron preparations. During pregnancy, it is used for the treatment of eclampsia but may cause reduced muscle tone or respiratory depression in the fetus, so continuous monitoring of the fetal condition is required; long-term use may also pose a risk of skeletal abnormalities in the fetus. During breastfeeding, safety has not been established, so it is advisable to avoid use unless absolutely necessary. Elderly patients may have decreased physiological function, so the rate of administration should be slowed down, and dosing should be adjusted. Severe side effects may occur with excessive dosing, so if symptoms appear, administration should be stopped immediately, and calcium preparations should be administered for detoxification. This medication should be slowly administered in a concentration of less than 10% when given intravenously, and mixing with certain other preparations may result in precipitation, so mixing should be avoided. Before use, ensure a sterile condition is maintained, and use immediately after opening; any unused portion should not be reused.

Serious side effects

conduction disorders, bradycardia, respiratory paralysis due to magnesium poisoning

Mild side effects

• Vomiting
• dry mouth
• headache
• heaviness
• tremors
• tingling
• flush
• peripheral vasodilation
• warmth at the administration site
• warmth

This medication should be stored in a sealed container to prevent air from entering and should ideally be kept at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and prevent degradation.

Appearance

A colorless, transparent liquid in a colorless, transparent plastic injection

Package unit

20mL/ampule (PE) X 50